68 results about "Mitoxantrone" patented technology

A group of new compounds, N-(all-trans-Retinoyl)-L-cysteic acid, N-(13-cis-Retinoyl)-L-cysteic acid, N-(all-trans-Retinoyl)-L-cysteinesulfinic acid, N-(13-cis-Retinoyl)-L-cysteinesulfinic acid, N-(all-trans-Retinoyl)-L-homocysteic acid, N-(13-cis-Retinoyl)-L-homocysteic acid, and sodium salts of these compounds, including sodium salts of their esters and amides, is shown to exhibit therapeutic effects per se, and which compounds in combination with cytotoxic compounds, such as docetaxel, paclitaxel, doxorubicin and mitoxantrone, exhibit a synergistic effect. These compounds make it possible to manufacture new formulations of poorly soluble pharmaceutical compounds, and the present invention discloses a process of manufacturing water-soluble formulations of such compounds, exemplified by docetaxel, and paclitaxel, exhibiting enhanced pharmacological activity, and formulations of water-soluble pharmaceuticals exemplified by doxorubicin and mitoxantrone, exhibiting improved therapeutic efficacy.

Disclosed is a bangosome injection of mitoxantrone or and its preparing technique. The injection comprises of mitoxantrone, phospholipid, cholesterol, anti oxidant additive, organic acid, alkali, sugar, buffer and water for injection, the preparing technique includes preparation of lipid film, packaging medicine, homogenization of bangosome, purifying or solidifying bangosome, constant volume, degerming, subpackage and reposition and so on. The has remarkable stability, high ratio of packaging medicine, low cost, few poisonous side-effect and simple preparing technique.

This invention pertains to liposomal formulations of mitoxantrone and methods for their manufacture and use. The compositions of the present invention include liposomal formulations of mitoxantrone in which the liposome contains any of a variety of neutral or charged liposome-forming materials in addition to a compound that is thought to bind mitoxantrone, such as cardiolipin. The liposomal compositions can be used advantageously in conjunction with secondary therapeutic agents other than mitoxantrone, including antineoplastic, antifungal, antibiotic among other active agents. Methods are provided in which a therapeutically effective amount of the formulation is administered to a mammal, such as a human.

The invention discloses a method for detecting mitoxantrone based on a molecularly imprinted polymer with quantum dot ratio fluorescence performance. The method comprises the following steps: preparing the mitoxantrone molecularly imprinted polymer with ratio fluorescence performance with a sol-gel method by taking red CdTe quantum dot@ SiO2 as a carrier, 3-aminopropyltriethoxysilane as a functional monomer, mitoxantrone as a template and tetraethoxysilane as a crosslinking agent in the presence of green CdTe quantum dots, wherein the polymer has holes being consistent with the sizes, shapes and functional groups of template molecules, and can be used for selectively recognizing mitoxantrone; implementing high-sensitivity detection of the mitoxantrone directly with a ratio fluorescence method. Compared with the original chromatography and electrochemical method, the detection method has the advantages that operation become easier, the detection speed becomes higher, the cost is lower, the analysis rate is increased greatly, and trace detection of the mitoxantrone can be realized.

The invention relates to the novel usage of an antimalarial medicine, in particular to the novel usage of hydroxychloroquine having sensitivity enhancing effect on various chemical anti-multiple myeloma medicaments. The novel usage is characterized in the application of hydroxychloroquine in treatment of multiple myeloma through chemotherapeutic medicaments. The hydroxychloroquine can obviously enhance the killing activity of chemotherapeutic medicines such as doxorubicine, epidoxorubicin, cis-platinum and mitoxantrone to multiple myeloma cells, and the killing activity thereof is realized by inhibiting the myeloma cell autophagy signals by hydroxychloroquine. Hydroxychloroquine can induce the quantity of the autophagy lysosomes of the multiple myeloma cells to be increased and the expression of the autophagy-associated albumen LC3-II to be increased.

A group of new compounds, N-(all-trans-Retinoyl)-L-cysteic acid, N-(13-cis-Retinoyl)-L-cysteic acid, N-(all-trans-Retinoyl)-L-cysteinesulfinic acid, N-(13-cis-Retinoyl)-L-cysteinesulfinic acid, N-(all-trans-Retinoyl)-L-homocysteic acid, N-(13-cis-Retinoyl)-L-homocysteic acid, and sodium salts of these compounds, including sodium salts of their esters and amides, is shown to exhibit therapeutic effects per se, and which compounds in combination with cytotoxic compounds, such as docetaxel, paclitaxel, doxorubicin and mitoxantrone, exhibit a synergistic effect. These compounds make it possible to manufacture new formulations of poorly soluble pharmaceutical compounds, and the present invention discloses a process of manufacturing water-soluble formulations of such compounds, exemplified by docetaxel, and paclitaxel, exhibiting enhanced pharmacological activity, and formulations of water-soluble pharmaceuticals exemplified by doxorubicin and mitoxantrone, exhibiting improved therapeutic efficacy.

The invention discloses an application of a novel liposome-entrapped mitoxantrone combined chemotherapeutic drug in antineoplastic treatment. According to the invention, a new liposome-entrapped mitoxantrone preparation containing components such as cardiolipin is prepared internationally, and is used for being combined with other clinical routine first-line chemotherapeutics for antineoplastic treatment. The invention expounds the preparation method and symptom research of the novel liposome preparation, the preparation has the characteristics of high entrapment rate, uniform particle size distribution, good stability, prolongation of chemotherapeutics half life, and reduction of toxic and side effect; compared with other treatment methods, in breast cancer and leukemia tumor animal models, antineoplastic curative effect of the new liposome-entrapped mitoxantrone preparation and other chemotherapeutics is more obvious.

Disclosed is an anticancer slow release agent which comprises slow release microspheres and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The anticancer antibiotics are selected from Idarubicin, Valtaxin, Pirarubicin and Mitoxantrone, The anti-metabolite drugs are selected from Pemetrexed, Carmustine, Tegafur, Zalcitabine, Emtritabine, Galocitabine, Ibacitabine, Ancitabine, Decitabine, Flurocitabine, Enocitabine, Imidazoletabine, Capecittabine, Gemcitabine, Fludrarbine, Raltitrexed, Dexrazoxane, Cladribine, Nolatrexed and folic acid, The slow release auxiliary materials are selected from EVAc, Polifeprosan, sebacylic acid copolymer, lactic acid, the viscosity of the suspension adjuvant is 100-3000cp (at 25-30 deg C), and is selected from sodium carboxymethylcellulose. The slow release microspheres can also be prepared into slow release implanting agent for injection or placement in or around tumor.

The present invention discloses a preparation method and uses of an anti-cancer drug estrogen targeting PEG-modified liposome. The liposome preparation method comprises: synthesizing estrone-pegylated phospholipid from activated estrone, taking 40-80 parts by weight of phospholipid, 5-45 parts by weight of cholesterol, and 5-40 parts by weight of pegylated phospholipid, dissolving in methanol, carrying out rotary evaporation, adding an ammonium sulfate aqueous solution, carrying out dialysis, adding 0.5-10 parts by weight of mitoxantrone, carrying out incubation, carrying out dialysis, adding 0.1-20 parts by weight of the estrone-pegylated phospholipid, carrying out incubation, and filtering with a membrane to obtain the liposome preparation. Compared with the liposome in the prior art, the obtained estrogen targeting PEG-modified liposome has characteristics of high encapsulation efficiency, uniform particle size, pharmacokinetics improving, anti-tumor efficacy enhancing, toxicity reducing, simple preparation process and easy scale-up production, and is expected to become the novel pharmaceutical preparation for cancer therapy. The uses are targeted treatments of breast cancer, leukemia and other cancers.

The invention discloses a method for detecting mitoxantrone based on a luminous gold nanocluster. The method comprises the following steps: preparing the gold nanocluster, measuring fluorescence intensity of the gold nanocluster at a position with wavelength of 619 nm and recording as F0 under excitation of 469nm-wavelength light; after adding mitoxantrone with different weight in the step I, measuring the fluorescence intensity of the gold nanocluster containing the mitoxantrone with different concentrations and recording as F at the position with wavelength of 619 nm under excitation of 469nm-wavelength light, calculating out linear relation between change value of the fluorescence intensity of the gold nanocluster before and after adding the mitoxantrone and mitoxantrone concentration; adding a to-be-detected sample into the gold nanocluster, and testing the change value of the fluorescence intensity at the position with wavelength of 619 nm under excitation of 469nm-wavelength light before and after adding the mitoxantrone, calculating the weight or concentration of the added mitoxantrone to establish detection according to the obtained linear relation. The method has characteristics of being high in selectivity, high in sensitivity, simple and convenient, easy to implement, and the like.

An antineoplastic medicinal composition used to prepare the medicines for treating breast cancer and leukemia contains the epigallocatechin gallate and mitoxantrone in weight ratio of (1-2000): (1-5).

The invention discloses nano-scale mesoporous silicon dioxide-methotrexate-mitoxantrone nanoparticles. Its preparation method is disclosed, that is, amino functionalized mesoporous silica nanoparticles (MSNN) are prepared by modifying amino groups on the surface of mesoporous silica nanoparticles, and then the amino groups of MSNN are covalently combined with MTX to form methotrexate ‑Amino-modified mesoporous silica nanoparticles (MSNN‑MTX), and finally load mitoxantrone into the nanopores of MSNN‑MTX to obtain nanoscale mesoporous silica‑methotrexate/mitoxantrone Quinone nanoparticles (MSNN‑MTX/MIT). Its antitumor effect is disclosed. Compared with the combined application of conventional MTX and MIT, MSNN‑MTX/MIT significantly prolongs the survival time of S180 mice, improves the curative effect and reduces systemic toxicity. Therefore, the present invention discloses the application of MSNN-MTX/MIT in the preparation of antitumor drugs combined with MTX and MIT. The MSNN-MTX/MIT of the present invention has a good clinical application prospect.

The present invention relates to the technical field of medicine and particularly relates to an antitumor lymphatic metastasis function of mitoxantrone and a pharmaceutical preparation of the mitoxantrone. The mitoxantrone is administered locally, such as intratumoral administration and peritumoral and tumor subcutaneous administration. The mitoxantrone can be prepared into the clinically acceptable pharmaceutical preparation with a pharmaceutically acceptable carrier. The pharmaceutical preparation is a parenteral administration preparation. The parenteral administration preparation is selected from a solution, a liposome, a dendritic macromolecule, a nanoparticle, a nanocrystal, a microcrystal, a microsphere and a gel agent. The mitoxantrone is used for local chemotherapy to increase anti-tumor activity, reduces toxic and side effects, targets a lymphatic system, inhibits tumor lymphatic metastasis, can reduce tumor volume and is convenient for subsequent surgical resection when usedfor neoadjuvant chemotherapy, can also kills tumor cells metastasized in lymphatic vessels, reduces risks of postoperative tumor recurrence, and improves quality of life of patients.

A double sustained release anticancer gel sustained release injection consists of anticancer medicine and amphiphilic block copolymer hydrogel, wherein the anticancer medicine comprises vincristine, vinorelbine, vinblastine, daunomycin, mitoxantrone, mitozolomide and temozolomide, etc., and exists in sustained release preparation injection in the forms of sustained release microsphere, microsphere or micropowder, i.e. the anticancer medicine in anticancer useful quantity is partly or completely wrapped inside the sustained release microsphere. Sustained release gel has temperature-sensitive gelling characteristics and is in the state of fluxible liquid in an environment with the temperature lower than body temperature; moreover, the sustained release gel can be automatically converted into non-flowing water-insoluble gel capable of biodegradation and absorption inside the body of a warm blood so as to slowly release medicine inside part of a tumor; the sustained release microsphere is propitious to release medicine smoothly and slowly, and double sustained release is propitious to control tumor cells entering a dormancy stage; moreover, the medicine which exists in the sustained release gel in the form of micropowder is propitious to release the medicine relatively faster and to control cells in faster proliferation. The double sustained release anticancer gel sustained release injection can used together with radiotherapeutic particle, etc.

The invention relates to a TOP medicament resistant cell line human ovarian cancer, with a accession number of CGMCC No 1217, which is selecting human ovarian cancer cell line as parental cell, putting the cell into RPMI1640 culture medium containing 15% calf serum, putting into incubator with 5% CO2 and 37 DEG C to culture; acquiring cells in logarithmic growth phase, counting after digesting with 0.25% pancreatin, inoculating 5*105/ml into culture bottle according to amount of 5ml in each bottle, when cells adheres to wall after 24 hours, reacting for 2 hours with a TOP final content of 2160ng/ml, discarding culture medium, washing by phosphate buffer for 3 times, replacing fresh culture medium, second impulsing after growing is resumed, and repeatedly operating, until it is impulsed with medicament for 13 times. The cell line is constructed for 10 months, medicament resistance of cell is 10.67 per cell, P<0.01 comparing with sensitive cell, has cross resistance to mitoxantrone, camptothecin, vincristine besides resistance to TOP.

The invention discloses a preparation method and application of a polycarbonate drug-loaded nano chemosensitizer based on nitric oxide. The sensitizer is prepared by self-assembling a polycarbonate block copolymer containing a nitric oxide donor and a small molecule chemotherapeutic drug. The polycarbonate drug-loaded nano chemosensitizer based on nitric oxide has the advantages of good water solubility, small toxic and side effects, good stability in a normal physiological environment and the like, and effectively solves the problems of poor water solubility, large toxic and side effects and the like of indissolvable chemotherapeutic drugs such as adriamycin, mitoxantrone and the like in clinical use. The polycarbonate drug-loaded nano chemosensitizer based on nitric oxide also has the features that the drug-loading capacity is high, the tumor targeting property is remarkable, the tumor microenvironment can be regulated and controlled, the ideal chemotherapy sensitization effect is achieved, and tumor recurrence is reduced.

The invention relates to an improved mesenchymal stem cell (MSC) culture medium, bone marrow mesenchymal stem cells (BMSCs) and a culture method and application of the BMSCs. The improved MSC culturemedium comprises a base culture medium, a first component and melatonin, wherein the first component is selected from at least one of coenzyme Q10 and mitoxantrone mesylate, the working concentrationof the first component is 1-20 [mu]M, the working concentration of the melatonin is 1-20 [mu]M, and the molar ratio of the first component to the melatonin is 1: (0.2-10). The improved MSC culture medium can improve mitochondrial activity and mitochondrial quantity in MSCs.

The invention belongs to the field of antiviral drugs, and discloses an application of a DNA topoisomerase inhibitor in preparation of medicines for preventing and/or treating novel coronavirus infection, and the DNA topoisomerase inhibitor comprises mitoxantrone, doxorubicin or pharmaceutically acceptable salts of above small molecule compounds. DNA topoisomerase inhibitors such as mitoxantrone and doxorubicin can extremely strongly inhibit the synthesis of novel coronavirus virus SARS-CoV-2 replicon RNA and reduce the RNA copy amount of wild novel coronavirus virus SARS-CoV-2 in cells, so that the replication of novel coronavirus SARS-CoV-2 is inhibited, and the effect of preventing and/or treating novel coronavirus SARS-CoV-2 infection is achieved.